Which startup will cure hair loss?

Which startup will cure hair loss?

What would a real hair-loss cure actually do?

A real hair-loss cure would bring back visible hair after a short treatment and keep it growing once the treatment ends.

That definition removes most products from the race. Minoxidil can stimulate growth, finasteride can slow further loss, and transplants can move existing follicles. All three help many people, yet none restores the scalp’s own ability to replace lost follicles permanently.

There are two realistic versions of a future cure. The first would wake up miniaturized or dormant follicles and make them produce thick hair again for years. The second would create replacement follicles where the original ones have been destroyed. The first route looks clinically reachable. The second remains much further away.

For this article, we call it a cure when it restores hair that current medicines cannot recover and avoids another daily treatment for life. A cure could still work only for certain people or certain types of alopecia.

Are hair-loss startups even trying to cure the same disease?

Hair-loss startups are chasing several different diseases, so one company is unlikely to cure every kind of baldness.

Most companies in this race are working on androgenetic alopecia, the common form of male and female pattern hair loss. Genetically vulnerable follicles gradually shrink. The hairs become thinner, grow for less time and may eventually become almost invisible.

Alopecia areata works differently. The immune system attacks follicles and can cause sudden bald patches or complete hair loss. Immune-blocking JAK medicines have recently transformed treatment for some patients, although relapses remain common and dermatologists still do not describe the disease as cured.

Scarring alopecias create an even harder problem because inflammation can destroy the follicle itself. A drug that wakes up a sleeping follicle may help pattern baldness while offering little to someone whose follicles have disappeared.

Pelage, Amplifica, Absci, Hope Medicine, Eirion and Veradermics therefore belong mainly in the pattern-hair-loss race. dNovo is one of the few startups aiming at the deeper problem of replacing follicular cells.

Why is pattern baldness still so hard to reverse?

Pattern baldness is hard to reverse because every follicle is a tiny living organ with several systems working together.

A healthy follicle coordinates stem cells, dermal papilla cells, blood vessels, connective tissue, hormones and several growth pathways. Restarting one part may produce a few extra hairs. Rebuilding natural density requires the whole system to work together for repeated growth cycles.

Researchers once hoped that balding scalps mainly contained sleeping stem cells waiting for the right trigger. That idea still looks useful, but newer single-cell studies show a messier picture. Balding follicles can also lose progenitor cells, receive weaker growth instructions and develop changes in the tissue around them.

Human biology adds another difficulty. Mouse hair grows quickly and synchronously, which makes dramatic regrowth easier to show. Human scalp hairs grow over years, react differently across the hairline and crown, and must emerge with the right thickness, angle, color and direction. Many treatments that look spectacular on mice never clear that bar.

The field is more credible now because several new mechanisms have reached controlled human studies. Trials are testing stem-cell activation, prolactin-receptor blockade, injectable growth molecules and improved oral minoxidil. The gap between interesting science and a useful product is finally being tested in people.

Which company is closest to changing hair-loss treatment today?

Veradermics is closest to a major new product, while Pelage is closest to a treatment that could feel like a cure.

Veradermics has the most advanced clinical program and the largest human dataset. Its extended-release oral minoxidil has already produced positive late-stage results in men, and its latest study in women also showed substantial growth. Approval would give doctors a purpose-built oral treatment for pattern hair loss.

Pelage is earlier in clinical testing and is trying something more ambitious. PP405 aims to restart dormant follicular stem cells, and its controlled human study found new terminal hairs coming from previously inactive follicular units.

Amplifica has an intriguing durability result after one injection cycle. Absci has cleared its first human safety hurdle. Hope Medicine completed a large mid-stage trial but still has not released the result. Eirion has a fast early readout from only 24 people. dNovo remains in animal testing.

Company	Where it stands now	What it could deliver	Our take
Veradermics	Late-stage trials	A stronger oral treatment	Closest to market
Pelage Pharmaceuticals	Preparing late-stage studies	Dormant follicles produce thick hair again	Best cure-like startup
Amplifica	First human study completed	Months of growth after a short injection cycle	Strongest outsider
Absci	Phase 1 underway	Infrequent antibody injections restart growth	Serious, still early
Hope Medicine	Phase 2 completed	Prolactin-receptor blockade works in humans	Impossible to rank without results
Eirion Therapeutics	Small first-in-human study	Fast topical regrowth	Interesting, weak proof
dNovo	Animal testing	Replacement follicles for irreversible baldness	Most ambitious, least proven

If you want more recent data on this point, please see our latest biotechnology market report.

Will Veradermics cure hair loss?

Veradermics could deliver the biggest treatment upgrade in decades, but it will not cure pattern baldness.

Its drug, VDPHL01, is an extended-release version of minoxidil. The new formulation keeps the drug circulating more steadily and may expose follicles to an effective dose without the sharp blood-level peak of ordinary oral minoxidil.

In a randomized late-stage study of 519 men, the once-daily and twice-daily groups gained an average of 30.3 and 33.0 non-vellus hairs, meaning thicker visible hairs, per square centimetre after six months. Placebo added 7.3.

The drug therefore produced roughly four times the raw gain seen with placebo, or about 23 to 26 extra hairs per square centimetre. Around 79% of once-daily patients and 86% of twice-daily patients reported improvement, compared with about 36% on placebo.

The latest female study added useful data. Twenty-eight women gained roughly 23 non-vellus hairs per square centimetre after six months, and close to nine in ten reported better coverage. That study was open-label, so the larger randomized female trial will carry much more weight.

These numbers make Veradermics the clearest near-term winner. The company is now publicly traded, which takes it out of the literal startup race while setting the standard every private contender must beat.

VDPHL01 remains a better delivery system for an old growth stimulant. Patients would probably need to keep taking it, and the genetic process that shrinks vulnerable follicles would continue in the background.

Is Pelage Pharmaceuticals the startup to beat?

Yes. Pelage is currently the strongest private startup in the race to produce cure-like hair regrowth.

PP405 changes the metabolism of hair-follicle stem cells. The goal is to push dormant cells back into an active state so the follicle can make a thick terminal hair again. That approach goes closer to the source of the problem than another stimulant or hormone blocker.

The product also looks practical to develop. The topical treatment showed no detectable drug in the bloodstream in its reported study and has already produced controlled human results.

At the latest American Academy of Dermatology meeting, the company put extra emphasis on active follicular-unit counts. That measure is designed to show whether previously silent units begin producing hair.

Pelage also has the money to finish the job. It raised $120 million after its Phase 2a result and is preparing late-stage studies. That amount should cover the large, long and expensive trials a regenerative treatment needs.

The lead is still narrow. Its clinical dataset comes from 78 participants, and the strongest result appeared in a selected group of men with more advanced loss. No other private company has shown the same mix of a new mechanism, human results and enough money to run late-stage trials.

If you want more recent data on this point, please see our latest biotechnology market report.

Does PP405’s human evidence really hold up?

PP405’s trial is good enough to take seriously and far too small to call a cure.

The randomized Phase 2a study enrolled 78 men and women. Participants used PP405 or placebo for four weeks and were followed for another eight.

Among men with more advanced hair loss, 31% of treated participants achieved more than a 20% rise in hair density by week eight. None of the placebo participants in that group crossed the same threshold.

For an early study, the gap between the two groups is impressive. It also means that 69% of the highlighted treated group failed to reach the company’s chosen response level. Pelage has not publicly provided enough detail to calculate the average cosmetic benefit across the whole trial or to know how large that subgroup was.

The most interesting finding came from mapped follicular units, the small natural groups in which scalp hairs grow. Pelage reported thick terminal hairs growing from units that had produced no visible hair before treatment.

That supports follicle reactivation, although a severely miniaturized hair can be almost invisible. The trial cannot yet prove that a dead follicle came back to life.

The next study needs to answer three questions: how many people respond, how visible the change is, and how long the new hair survives without treatment. PP405 has earned a late-stage test. Calling it a cure already would be premature.

Could Amplifica beat Pelage with a few injections?

Amplifica could beat Pelage on convenience and durability, although the company has disclosed too little data to take the lead.

AMP-303 is injected directly into the scalp. In its first human study, each participant received the drug on one side of the frontal-temporal area and placebo on the other. That within-person design removes much of the noise caused by genetics, age and baseline hair density.

Amplifica said its responder rate was statistically significant: some participants gained more than 15% additional non-vellus hairs over placebo after 60 days. The advantage remained above 10% after 150 days, and the company also saw fine hairs becoming thicker terminal hairs.

Five months of measurable benefit after one treatment cycle would be a real advance. Many people tolerate occasional injections more easily than a daily pill or topical foam, especially when the result continues after the appointment.

But Amplifica leaves out the numbers we need. It has never disclosed the total sample size, the exact response rate, the average hair-count difference or the identity of AMP-303.

Its website has also produced no larger efficacy update since that first study. Pelage remains ahead until Amplifica publishes a fuller dataset or begins a clearly defined next trial.

Has Hope Medicine gone quiet for a bad reason?

The silence around Hope Medicine’s HMI-115 is now a serious weakness in the program.

HMI-115 blocks the prolactin receptor, a new target in hair biology. An early open-label study in 12 men found an average gain of about 14 non-vellus hairs per square centimetre after 24 weeks. Four women also took part, but that tiny uncontrolled study could only justify a larger test.

Hope Medicine then completed a randomized Phase 2 trial in 192 men. Few novel hair-loss drugs have reached a controlled study that large, so the trial should have given a clear answer about the target.

ClinicalTrials.gov currently lists the study as completed, yet the main efficacy result has never appeared publicly. Successful biotech companies usually announce a clear mid-stage win, especially in a consumer market this large.

Delays can come from analysis, publication plans or regulatory discussions, so silence alone cannot prove failure. Still, it lowers the program’s rank. Quite a lot, at this point.

Hope Medicine may still surprise the field. Until it publishes the trial, it belongs below companies that have shown their data.

If you want more recent data on this point, please see our latest biotechnology market report.

Is Absci becoming a real threat in hair loss?

Absci has become a credible challenger now that ABS-201 looks safe in its first human groups and stays in the body for a long time.

ABS-201 is another antibody against the prolactin receptor, designed with Absci’s AI drug platform. Its animal results attracted attention because treated mice and balding macaques grew substantial hair, but animal regrowth has fooled this field many times.

The latest Phase 1 update is more useful. Absci reported that the drug was well tolerated across its blinded single-dose groups and estimated a half-life of at least 65 days.

That supports a schedule of only two or three injections over six months. The trial has now moved into multiple dosing in people with androgenetic alopecia.

Absci still has no human hair-growth result. Its first human regrowth data are expected later, with a fuller result planned after that. Until those numbers arrive, the long half-life tells us that dosing could be convenient, not that the treatment works.

Funding should not slow the program down. A recent $100 million financing included large healthcare investors and Eli Lilly, giving Absci room to prove whether its AI-designed antibody actually grows human hair.

Absci is publicly traded too, which keeps it out of the literal startup answer.

Is Eirion’s five-week result believable?

Eirion’s ET-02 result is worth following, but five weeks and 24 participants provide flimsy proof of lasting regrowth.

The first-in-human study tested a topical treatment in three groups of eight people: vehicle, a low dose and a higher dose. Eirion reported that the high dose produced six times the non-vellus hair increase of its combined comparison group after five weeks, along with thicker hair shafts.

Five weeks sounds impressive, although human scalp hair grows slowly. That window is unusually short for judging whether new hairs become visible, survive and complete a normal cycle.

The comparison was also unusually generous to Eirion. It combined the placebo group with the ineffective low-dose group, then compared the result with historical minoxidil data from another trial. A direct head-to-head study would be much more convincing.

ET-02 may have found a fast stem-cell pathway. For now, the result supports a larger six-month trial and little more.

If you want more recent data on this point, please see our latest biotechnology market report.

Can dNovo grow hair where the follicles are gone?

dNovo is aiming at the hardest and most valuable prize: creating replacement hair-producing cells for people whose follicles can no longer be rescued.

The company reprograms cells from skin, blood or fat into hair stem cells and dermal papilla cells, which help tell a follicle when to grow. Those cells would then be placed into the scalp to form new hair-producing structures.

In theory, this could help smooth bald areas and some forms of scarring alopecia that follicle-activating drugs cannot reach.

dNovo transplanted reprogrammed human cells into hair-deficient mice. Hair appeared after three weeks and became clearly visible during the second month. The experiment shows that the cells can help make hair in a mouse.

It says very little about whether thousands of new human follicles can be created safely, placed at natural angles and kept cycling for years.

The company’s public milestone page still ends with work completed in 2021, and we could find no listed human trial. Pelage’s latest $120 million round alone was more than 40 times dNovo’s disclosed $2.7 million seed round.

Cell therapy requires custom manufacturing, quality control and a surgical delivery method, so the capital gap is a practical obstacle.

Stemson Therapeutics showed how punishing this route can be. Stemson also developed lab-made follicular structures and shut down before human testing after struggling to finance the program.

At this stage, dNovo remains an ambitious research project with no human trial.

Can any startup regrow hair on a smooth bald scalp?

No startup has shown that it can restore dense, natural hair across a long-bald human scalp.

Most clinical candidates still need a living follicle. They may restart a dormant unit, thicken a miniaturized hair or extend the growth phase. A scalp can look bare while retaining many tiny follicles, so advanced-looking baldness does not always mean every follicle has vanished.

Once the follicle structure is destroyed, the problem changes. Drugs such as PP405, AMP-303 and prolactin-receptor antibodies have nothing obvious to activate. A cell-replacement approach or a transplant becomes necessary.

The future market will probably split in two. People with early or moderate thinning may receive a regenerative drug before too much structure is lost. People with smooth, long-established bald areas may still need surgery or lab-grown follicles.

The first company called a hair-loss cure will probably help the first group. A universal cure that rebuilds a fully bald scalp remains a separate and much harder invention.

Will women get the same hair-loss breakthrough as men?

Women are finally included in the leading programs, but the strongest efficacy data still come from men.

Pelage enrolled men and women in its Phase 2a trial, although the company’s clearest responder result came from men with more advanced loss. Absci’s program also includes both sexes, while Amplifica’s first study enrolled only younger men.

Veradermics has moved fastest in women. Its latest 28-person study found average gains of roughly 23 non-vellus hairs per square centimetre after six months. Almost nine in ten participants reported better coverage, and the company reported no treatment-related serious or cardiac events.

The study lacked a placebo group, so the ongoing randomized trial will decide how persuasive those numbers really are.

Female pattern hair loss is also less neatly explained by androgen biology than male pattern baldness. That uncertainty could favour treatments that act directly on follicle metabolism or the hair cycle instead of relying on hormone suppression.

Any company claiming a broad breakthrough will need convincing female data. Women have fewer approved oral options, and a safe non-hormonal treatment could fill a larger gap for them than for men.

Can the new treatments keep working after patients stop?

No startup has proved permanent regrowth after treatment ends, and that remains the biggest hole in every cure claim.

Pelage measured its highlighted response four weeks after a four-week course. That shows the effect survived briefly beyond dosing. It cannot tell us whether the same hairs remain after six months or several growth cycles.

Amplifica has the strongest early durability result. Its one treatment cycle still showed an advantage over placebo after 150 days.

Absci may require only two or three injections over six months because the antibody stays in the body for a long time, although that would still be continuous drug action.

A convincing cure trial would stop treatment and follow patients long enough to see whether the same follicles keep producing thick hair. The microscopic counts should also match standardized photos, patient reports and ratings from doctors who do not know which treatment each person received.

Candidate	Best durability data	What remains unanswered
PP405	Growth measured four weeks after dosing ended	Whether the gain survives for a year
AMP-303	Benefit reported 150 days after one cycle	Exact response rate and longer follow-up
ABS-201	Half-life of at least 65 days	Whether human hair grows at all
HMI-115	Six months of scheduled injections	Results and off-treatment persistence
VDPHL01	Six months of continuous daily use	What happens after patients stop
dNovo	Hair growth in mice after cell placement	Safety and lifelong cycling in humans

Which startup will cure hair loss?

Pelage Pharmaceuticals is the best answer as of now, although the first PP405 product would more likely be a long-lasting regenerative treatment than a permanent universal cure.

Pelage currently has the best mix of human results, a genuinely regenerative idea and a product that can be tested at scale. It is also the only private contender with both controlled clinical data and enough funding to run a serious late-stage program.

Amplifica is the closest private challenger, but the company still needs to reveal the size and full outcome of its study. Absci could jump the ranking when its first human regrowth data arrive.

Veradermics will probably reach patients first and may become the most successful product in the group. Its drug improves minoxidil rather than rebuilding the follicle, so it belongs in the treatment race more than the cure race.

Cell replacement remains the boldest long-term route. Personalized follicular cells could one day restore hair where the old follicles have disappeared, although no company has human proof yet.

So our answer is Pelage. It is currently the startup most likely to create the first hair-loss treatment that patients casually call a cure, probably through meaningful regrowth after a short course and occasional retreatment.

A permanent cure for a fully bald scalp will probably arrive later from cell replacement, and no startup is close to proving it now.

If you want more recent data on this point, please see our latest biotechnology market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.